Literature DB >> 16864979

IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy.

R J J van Neerven1, E F Knol, A Ejrnaes, P A Würtzen.   

Abstract

It is well established that both the production of IgE by B lymphocytes and the maturation and recruitment of eosinophils in late-phase reactions are dependent on the activation of allergen-specific type-2 T-helper cells. What is less well known is the fact that efficient activation of allergen-specific T cells upon low-dose exposure to allergens is critically dependent on IgE-mediated or -facilitated allergen presentation. In fact, changes in the level of IgE-mediated allergen presentation may account for many of the immunological effects described for specific immunotherapy or anti-IgE treatment. This review aims to summarize the current knowledge, and will discuss the clinical relevance of blocking IgG antibodies induced by specific immunotherapy and anti-IgE monoclonal antibodies that both interfere with IgE-mediated allergen presentation. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16864979     DOI: 10.1159/000094714

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  34 in total

1.  Structure of the omalizumab Fab.

Authors:  Rasmus K Jensen; Melanie Plum; Luna Tjerrild; Thilo Jakob; Edzard Spillner; Gregers Rom Andersen
Journal:  Acta Crystallogr F Struct Biol Commun       Date:  2015-03-20       Impact factor: 1.056

Review 2.  The use of biologics for immune modulation in allergic disease.

Authors:  Willem van de Veen; Mübeccel Akdis
Journal:  J Clin Invest       Date:  2019-03-18       Impact factor: 14.808

3.  Reduced in vitro T-cell responses induced by glutaraldehyde-modified allergen extracts are caused mainly by retarded internalization of dendritic cells.

Authors:  Bärbel Heydenreich; Iris Bellinghausen; Steffen Lorenz; Helene Henmar; Dennis Strand; Peter A Würtzen; Joachim Saloga
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

Review 4.  Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches.

Authors:  R Valenta; R Campana; K Marth; M van Hage
Journal:  J Intern Med       Date:  2012-08       Impact factor: 8.989

5.  IgE, but not IgG4, antibodies to Ara h 2 distinguish peanut allergy from asymptomatic peanut sensitization.

Authors:  X Hong; D Caruso; R Kumar; R Liu; X Liu; G Wang; J A Pongracic; X Wang
Journal:  Allergy       Date:  2012-10-25       Impact factor: 13.146

6.  IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB.

Authors:  Carol T Cady; Maree S Powell; Ronald J Harbeck; Patricia C Giclas; James R Murphy; Rohit K Katial; Richard W Weber; P Mark Hogarth; Syd Johnson; Ezio Bonvini; Scott Koenig; John C Cambier
Journal:  Immunol Lett       Date:  2009-12-30       Impact factor: 3.685

Review 7.  The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses.

Authors:  R Pettipher
Journal:  Br J Pharmacol       Date:  2007-10-29       Impact factor: 8.739

8.  Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells.

Authors:  L Xue; A Barrow; R Pettipher
Journal:  Clin Exp Immunol       Date:  2009-02-11       Impact factor: 4.330

9.  B cells establish, but do not maintain, long-lived murine anti-peanut IgE(a).

Authors:  D M Moutsoglou; S C Dreskin
Journal:  Clin Exp Allergy       Date:  2016-04       Impact factor: 5.018

Review 10.  Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives.

Authors:  Birgit Linhart; Rudolf Valenta
Journal:  Vaccine       Date:  2011-11-17       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.